
-
Edgewise Therapeutics NasdaqGS:EWTX Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Location: 1715 38th Street, Boulder, CO, 80301, United States | Website: https://edgewisetx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.101B
Cash
436.4M
Avg Qtr Burn
-29.57M
Short % of Float
20.26%
Insider Ownership
0.53%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Sevasemten (EDG-5506) Details Becker Muscular Dystrophy | Phase 2 Data readout | |
Sevasemten (EDG-5506) Details Becker Muscular Dystrophy | Phase 2 Data readout | |
EDG-7500 Details Hypertrophic cardiomyopathies (HCM) | Phase 2 Data readout | |
Sevasemten (EDG-5506) Details Duchenne muscular dystrophy, Rare diseases Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Sevasemten (EDG-5506) Details Rare diseases, Duchenne muscular dystrophy Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Sevasemten (EDG-5506) Details Rare diseases, Limb-Girdle Muscular Dystrophy, McArdle disease | Phase 2 Update | |
Sevasemten (EDG-5506) Details Becker Muscular Dystrophy | Phase 1b Update |